Cerebrospinal Fluid Adenosine Deaminase for the Diagnosis of Tuberculous Meningitis
Biomarkers in Medicine · 2023
DOI: 10.2217/bmm-2022-0838 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomarkers in Medicine, 2023. Verfasst von Ashok K Pannu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Nehru Hospital, Chandigarh, 160012, India. Hauptthemen laut MEDLINE: Tuberculosis, Meningeal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
A consensus on the diagnostic utility of cerebrospinal fluid adenosine deaminase (ADA) for tuberculous meningitis (TBM) is lacking.
Methods
Patients aged ≥12 years admitted with CNS infections were enrolled prospectively. ADA was measured with spectrophotometry.
Results
We enrolled 251 TBM and 131 other CNS infections. The optimal cutoff of ADA was calculated at 5.5 U/l against microbiological reference standard with area under curve 0.743, sensitivity 80.7%, specificity 60.3%, positive likelihood ratio 2.03 and negative likelihood ratio 3.12. The widely used cutoff value 10 U/l had specificity 82% and sensitivity 50%. The discriminating power was higher for TBM versus viral meningoencephalitis than bacterial or cryptococcal meningitis.
Conclusion
Cerebrospinal fluid ADA has a low-to-modest diagnostic utility. The diagnosis of tuberculosis (TB) of the brain is mainly made by testing cerebrospinal fluid, a clear liquid that flows in and around the brain and spinal cord. Adenosine deaminase (ADA) is a protein whose production and activity are increased in many diseases, such as TB. ADA testing in cerebrospinal fluid is widely used for the diagnosis of brain TB. However, the experts have split opinions regarding its confirmatory role. This study explores ADA measurement in cerebrospinal fluid for differentiating TB from other brain infections. The report says that this simple and inexpensive test can be helpful, but it cannot make or refute the diagnosis of brain TB and should only be considered along with other tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Nehru Hospital, Chandigarh, 160012, India.
- Department of Gastroenterology, Postgraduate Institute of Medical Education & Research, Nehru Hospital, Chandigarh, 160012, India.
- Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research, Research Block A, Chandigarh, 160012, India.
- Department of Radiodiagnosis, Postgraduate Institute of Medical Education & Research, Nehru Hospital, Chandigarh, 160012, India.
ORCID-Profile: Ashok K Pannu, Suresh Selvam, Nadim Rahman, Devender Kumar, Atul Saroch, Arun K Sharma, Sunil Sethi, Rakesh Yadav, Vikas Bhatia
Zitieren
APA
Pannu, A. K., Selvam, S., Rahman, N., Kumar, D., Saroch, A., Sharma, A. K., Sethi, S., Yadav, R., & Bhatia, V. (2023). Cerebrospinal Fluid Adenosine Deaminase for the Diagnosis of Tuberculous Meningitis. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2022-0838
Vancouver
Pannu AK, Selvam S, Rahman N, Kumar D, Saroch A, Sharma AK, et al. Cerebrospinal Fluid Adenosine Deaminase for the Diagnosis of Tuberculous Meningitis. Biomarkers in Medicine. 2023. doi:10.2217/bmm-2022-0838
BibTeX
@article{Pannu2023,
author = {Pannu, Ashok K and Selvam, Suresh and Rahman, Nadim and Kumar, Devender and Saroch, Atul and Sharma, Arun K and Sethi, Sunil and Yadav, Rakesh and Bhatia, Vikas},
title = {Cerebrospinal Fluid Adenosine Deaminase for the Diagnosis of Tuberculous Meningitis},
journal = {Biomarkers in Medicine},
year = {2023},
doi = {10.2217/bmm-2022-0838}
}
EUVIMED